Preferred Label : iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819;
NCIt synonyms : Allogeneic Anti-CD19 CAR T-cells FT819; TCR-Less Trac-1XX CAR-T Cells FT819; CAR19-T Cells FT819;
NCIt definition : A preparation of off-the-shelf (OTS) T-lymphocytes, generated from an induced pluripotent
stem cell (iPSC) line, that have been genetically modified to express a CD19 1XX chimeric
antigen receptor (CAR) that targets the tumor-associated antigen (TAA) CD19, linked
to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of
the TCR (T-cell receptor)/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and inserted into
the T-cell receptor alpha constant (TRAC) locus and edited for elimination of TCR
expression, with potential immunostimulating and antineoplastic activities. Upon administration,
the iPSC-derived allogeneic anti-CD19 1XX-CAR T-cells FT819 specifically recognize
and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor
cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed
in all B-cell lineage malignancies and normal B-cells. The CD19 1XX CAR T-cells include
a 1928zeta mutant, 1XX, which contains one instead of all three immunoreceptor tyrosine-based
activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation
and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells. By nullifying
the TCR, the possibility of graft versus host disease (GvHD) is eliminated.;
Molecule name : FT-819; FT 819;
NCI Metathesaurus CUI : CL1642610;
Origin ID : C176850;
UMLS CUI : C5447470;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
